BioCryst to Present at Upcoming Investor Conferences
Rhea-AI Summary
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its participation in three major investor conferences in May 2025:
- Citizens Life Sciences Conference in New York - May 8, 2025, at 9:00 a.m. ET
- Bank of America 2025 Health Care Conference in Las Vegas - May 14, 2025, at 1:40 p.m. ET
- RBC Capital Markets Global Healthcare Conference in New York - May 21, 2025, at 3:05 p.m. ET
Investors and interested parties can access live audio webcasts and replay recordings of these presentations through the Investors & Media section on BioCryst's website at biocryst.com.
Positive
- Increased visibility through participation in three major healthcare investor conferences
- Multiple opportunities for investor engagement across different financial institutions (Citizens, Bank of America, RBC Capital Markets)
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BCRX gained 4.86%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
- Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 9:00 a.m. ET.
- Bank of America 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 1:40 p.m. ET.
- 2025 RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 21, 2025, at 3:05 p.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
Which investor conferences will BioCryst (BCRX) attend in May 2025?
Where can I watch BioCryst's (BCRX) May 2025 investor conference presentations?
What time is BioCryst's (BCRX) presentation at the Bank of America Healthcare Conference 2025?
When is BioCryst's (BCRX) presentation at the RBC Capital Markets Healthcare Conference 2025?
Which cities are hosting BioCryst's (BCRX) investor conferences in May 2025?
